TCGA-A8-A09D-01A-11R-A00Z-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 51
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- ADIPOGENESIS+0.370
- MITOTIC_SPINDLE+0.340
- TGF_BETA_SIGNALING+0.330
- ANGIOGENESIS+0.320
- HEDGEHOG_SIGNALING+0.320
- APICAL_JUNCTION+0.290
- UV_RESPONSE_DN+0.280
- COMPLEMENT+0.240
- CHOLESTEROL_HOMEOSTASIS+0.220
Top 10 suppressed
- DNA_REPAIR-0.260
- TNFA_SIGNALING_VIA_NFKB-0.260
- MYC_TARGETS_V1-0.150
- ESTROGEN_RESPONSE_EARLY-0.120
- ESTROGEN_RESPONSE_LATE-0.120
- GLYCOLYSIS-0.100
- E2F_TARGETS-0.090
- KRAS_SIGNALING_DN-0.060
- SPERMATOGENESIS-0.050
- UNFOLDED_PROTEIN_RESPONSE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_XGSA3GQE | pilocytic astrocytoma | — | 0.715 |
| 2 | MBCProject_3216_T1_RNA | — | A | 0.715 |
| 3 | SNU886_LIVER | HCC | — | 0.702 |
| 4 | TCGA-BH-A18F-01A-11R-A12D-07 | — | A | 0.694 |
| 5 | TCGA-BH-A0C3-01A-21R-A12P-07 | — | A | 0.694 |
| 6 | MBCProject_0065_T1_RNA | — | C | 0.692 |
| 7 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.691 |
| 8 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.691 |
| 9 | MBCProject_0698_T1_RNA | — | A | 0.688 |
| 10 | MBCProject_0209_T1_RNA | — | C | 0.687 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |